New Vaccine to Stop Cancer
New Vaccine to Stop Cancer
防止癌症的新疫苗
Introduction
The University of Oxford and Moderna made a new vaccine. This vaccine helps people who might get cancer because of their family history. Tests start this summer.
牛津大學與 Moderna 開發了一款新疫苗。這款疫苗能幫助那些因家族病史而可能罹患癌症的人。測試將於今年夏天開始。
Main Body
Some people have a problem with their DNA. This problem gives them a high risk of cancer in the colon or ovaries. The vaccine teaches the body to find and kill bad cells before they become cancer.
有些人的 DNA 存在問題，這使得他們患結腸癌或卵巢癌的風險很高。該疫苗會教導身體在壞細胞變成癌症之前，就將其發現並予以清除。
Moderna and Cancer Research UK help with this work. First, doctors want to find the right amount of vaccine. They also want to make sure the vaccine is safe for people.
Moderna 與英國癌症研究中心（Cancer Research UK）協助此項工作。首先，醫生希望找出正確的疫苗劑量，同時也要確保該疫苗對人體是安全的。
This vaccine might work for many types of cancer. If it works, doctors can use this method to stop other types of cancer too.
這款疫苗可能對多種癌症有效。如果成功，醫生可以使用此方法來防止其他類型的癌症。
Conclusion
Doctors are testing the vaccine now. They will do more tests in 2027.
醫生目前正在測試該疫苗，並將在 2027 年進行更多測試。
Vocabulary Learning
⚡ The 'Power' of Can and Might
In this story, we see two words that talk about the future and possibility. For an A2 learner, knowing the difference is key.
1. Might (Maybe/Not Sure) We use might when we are guessing. It is not 100% certain.
- Example: "This vaccine might work for many types of cancer."
- Meaning → It is possible, but we don't know for sure yet.
2. Can (Ability/Power) We use can when something is possible because of a skill or a tool.
- Example: "Doctors can use this method to stop other types of cancer."
- Meaning → They will have the power/ability to do it.
Quick Pattern Guide:
- Uncertainty → Might
- Ability → Can
Words to remember from the text:
- Safe (Not dangerous)
- Right amount (The correct size/number)
Vocabulary Learning
Clinical Trials Begin for mRNA Cancer Vaccine Targeting Lynch Syndrome
針對林奇症候群的 mRNA 癌症疫苗開始進行臨床試驗
Introduction
The University of Oxford and Moderna have created an mRNA vaccine to prevent cancer in people with Lynch syndrome. Clinical trials for this new treatment are scheduled to begin this summer.
牛津大學與 Moderna 研發了一款 mRNA 疫苗，用以預防林奇症候群患者罹患癌症。這項新療法的臨床試驗預計將於今年夏天開始。
Main Body
The Intercept-Lynch trial focuses on the mRNA-4194 vaccine, which is designed for people with a genetic condition that prevents their bodies from repairing DNA. This deficiency greatly increases the risk of developing colorectal, ovarian, and endometrial cancers. The vaccine works by using mRNA technology as a set of instructions, which allows the immune system to find and destroy pre-cancerous cells before they become malignant.
Intercept-Lynch 試驗聚焦於 mRNA-4194 疫苗，該疫苗是為患有基因缺陷而導致身體無法修復 DNA 的人群所設計。這種缺陷會大大增加罹患大腸癌、卵巢癌及子宮內膜癌的風險。疫苗利用 mRNA 技術作為一套指令，讓免疫系統在癌前細胞轉變為惡性之前，就能地發現並摧毀它們。
This project is Moderna's first time using mRNA technology specifically to prevent cancer, and it is supported by Cancer Research UK. The first phase of the study aims to find the correct dose, ensure the vaccine is safe, and analyze how the immune system responds. If these results are successful, a larger second phase involving multiple centers is expected to start in 2027.
此計畫是 Moderna 首次專門使用 mRNA 技術來預防癌症，並得到了英國癌症研究基金會 (Cancer Research UK) 的支持。研究的第一階段旨在確定正確劑量、確保疫苗安全性，並分析免疫系統的反應。若結果成功，預計將於 2027 年啟動涉及多個中心的更大規模第二階段試驗。
Researchers emphasize that the vaccine targets markers found in several different Lynch-related cancers, which could provide wide-ranging protection. Furthermore, the University of Oxford suggests that if this method works, it could be adapted to prevent other types of cancer that are not related to Lynch syndrome.
研究人員強調，該疫苗針對在數種不同林奇相關癌症中發現的標記，能提供廣泛的保護。此外，牛津大學建議，如果此方法有效，未來可將其調整以預防其他與林奇症候群無關的癌症類型。
Conclusion
The project is currently starting safety and effectiveness trials, with larger clinical tests planned for 2027.
該計畫目前正開始進行安全性與有效性試驗，更大規模的臨床測試計劃於 2027 年進行。
Vocabulary Learning
🚀 From 'Simple' to 'Sophisticated'
At the A2 level, you likely use basic verbs like help, do, or make. To reach B2, you need Precise Action Verbs. Look at how this text describes scientific processes. It doesn't just say "the vaccine helps"; it uses words that describe how it helps.
⚡ The Power Move: Precision Verbs
| A2 Style (Simple) | B2 Style (Precise) | Why it's better |
|---|---|---|
| help the body | prevent cancer | It specifies that the cancer won't start |
| fix DNA | repair DNA | 'Fix' is general; 'repair' is technical and professional |
| stop cells | destroy cells | It describes the complete elimination of the threat |
| change the method | adapt the method | It means changing something to fit a new purpose |
🛠️ Logic Connectors for Fluency
B2 speakers don't just list facts; they link ideas to show cause and effect. Notice the word "Furthermore" in the text.
Instead of saying: "The vaccine targets many cancers. Also, it can be used for other cancers."
A B2 speaker says: "The vaccine targets several cancers. Furthermore, it could be adapted for other types."
Pro Tip: Use Furthermore or Moreover when you want to add a stronger, more important point to your argument. It signals to the listener that you are building a complex case, not just making a list.
💡 Quick Shift: The 'Passive' Vibe
Check this phrase: "...is expected to start in 2027."
An A2 student says: "I think it will start in 2027."
A B2 student uses the passive-style structure (is expected to) to sound more objective and formal. Use this when you aren't 100% sure, but the general consensus or plan says it will happen.
Vocabulary Learning
Initiation of Clinical Trials for mRNA-Based Cancer Preventative Vaccine Targeting Lynch Syndrome.
針對 Lynch 症候群的 mRNA 癌症預防疫苗啟動臨床試驗
Introduction
The University of Oxford and Moderna have developed an mRNA vaccine designed to prevent malignancy in individuals predisposed to Lynch syndrome, with clinical trials scheduled for the current summer season.
牛津大學與 Moderna 開發了一款 mRNA 疫苗，旨在預防 Lynch 症候群高風險個體的惡性腫瘤，臨床試驗預計於今年夏季展開。
Main Body
The Intercept-Lynch trial focuses on the administration of the mRNA-4194 vaccine to a cohort characterized by a hereditary deficiency in DNA repair mechanisms. This genetic predisposition significantly elevates the lifetime probability of developing colorectal, ovarian, and endometrial carcinomas, among other malignancies. The mechanism of action involves the utilization of mRNA technology to serve as a biochemical instructional framework, thereby enabling the immune system to identify and neutralize pre-cancerous cellular abnormalities before malignant transformation occurs.
Intercept-Lynch 試驗重點在於將 mRNA-4194 疫苗施用於具有 DNA 修復機制遺傳缺陷的群體。這種基因傾向顯著提升了個體一生中罹患大腸癌、卵巢癌及子宮內膜癌等惡性腫瘤的機率。其作用機制是利用 mRNA 技術作為生化指令框架，使免疫系統能在細胞發生惡性轉化前，識別並中和癌前細胞的異常。
Institutional positioning indicates that this venture represents Moderna's inaugural application of mRNA technology specifically for oncological prevention. The collaboration is further supported by Cancer Research UK. The primary phase of the study is designed to determine the optimal dosage, evaluate systemic safety, and analyze the resulting immune responses. Should these initial parameters be validated, a multi-center second phase is projected to commence in 2027.
機構定位指出，此項目代表 Moderna 首次將 mRNA 技術專門應用於癌症預防。該合作 further 得到了英國癌症研究中心 (Cancer Research UK) 的支持。研究的第一階段旨在確定最佳劑量、評估全身安全性，並分析隨之而來的免疫反應。若這些初步參數獲得驗證，預計將於 2027 年啟動多中心第二階段研究。
Regarding the scalability of this intervention, investigators suggest that the targets selected for the vaccine are shared across various Lynch-associated cancers, potentially providing broad-spectrum protection. Furthermore, the University of Oxford posits that the successful establishment of this proof of principle may facilitate the adaptation of this methodology for the prevention of other cancer types not associated with Lynch syndrome.
關於此干預措施的可擴展性，研究人員指出疫苗選擇的目標在各種 Lynch 相關癌症中是共用的，可能提供廣譜保護。此外，牛津大學認為，成功建立此概念驗證後，可能會促進將此方法轉用於預防其他非 Lynch 症候群相關的癌症類型。
Conclusion
The current phase of the project involves the immediate commencement of safety and efficacy trials, with expanded clinical testing anticipated by 2027.
該項目目前階段為立即展開安全性與有效性試驗，預計於 2027 年擴大臨床測試。
Vocabulary Learning
The Architecture of Nominalization and 'The Static Verb'
To transition from B2 to C2, a student must stop focusing on who is doing what (active agency) and begin focusing on the state of the phenomenon (conceptual agency). This text is a masterclass in Nominalization—the process of turning verbs and adjectives into nouns to create an objective, academic distance.
⚡ The C2 Pivot: From Action to Entity
Look at the phrase: "The successful establishment of this proof of principle may facilitate the adaptation of this methodology..."
B2 approach (Action-oriented): "If they successfully establish this principle, they can adapt the method..." C2 approach (Entity-oriented): "The successful establishment... may facilitate the adaptation..."
In the C2 version, the 'action' (establishing/adapting) is frozen into a 'noun' (establishment/adaptation). This removes the need for a human subject ("they"), shifting the focus onto the conceptual validity of the research rather than the researchers themselves.
🔍 Linguistic Dissection: The 'Noun-Heavy' Chain
Notice the density of the following string:
"...a cohort characterized by a hereditary deficiency in DNA repair mechanisms."
Instead of saying "people whose DNA cannot repair itself because of their genes," the author employs a Noun Chain:
Cohort Deficiency Mechanisms.
This creates a high-density information packet. At C2, your goal is to increase the lexical density of your prose. You do this by replacing clauses with complex noun phrases.
🛠 Strategic Application for the Student
To emulate this, practice the 'Verb-to-Noun' Shift:
| B2 Verb-Centric Logic | C2 Nominalized Logic |
|---|---|
| Because the vaccine is scalable... | Regarding the scalability of this intervention... |
| We need to determine the dose... | ...designed to determine the optimal dosage... |
| They are predisposed to get cancer... | ...individuals predisposed to malignancy... |
The Scholarly Takeaway: C2 mastery is not about using 'big words'; it is about manipulating the grammar of the sentence to prioritize the concept over the actor.